Stereotaxis Inc (STXS) Stock Forecast & Price Target

Stereotaxis is viewed positively because its 2026 transition is already producing tangible regulatory and commercial catalysts, including GenesisX, MAGiC ablation, and Synchrony approvals, while catheter revenue crossed $1 million in 2Q26 and recurring revenue rose 7.5% year over year to $6.2 million. The company’s core appeal lies in its high-margin razor/razor-blade model, where a broader installed base and improving catheter utilization can compound system placements, with management targeting more than $1 million in capital sales in both 3Q and 4Q and at least 5 GenesisX placements this year. Despite near-term supply and transition headwinds, the outlook is constructive because cash flow profitability is expected in 1H27, full-year revenue is guided above $40 million, and stronger manufacturing capacity could unlock materially greater growth into 2027.

Stereotaxis is facing a deteriorating near-term operating profile, with 1Q revenue of $6.3M and Q2 revenue of $7.7M both missing expectations, while system sales remain especially weak at $1.3M and $1.5M, respectively. Although recurring revenue and robotic catheter sales are improving, the company still shows limited scale, with adjusted operating losses of $2.1M in Q2, elevated operating expenses of $9.1M, and a 2026 revenue estimate of $34.5M that still implies only modest system sales of $8.3M. The negative outlook is further supported by execution and balance-sheet risk, including slow technology adoption, potential regulatory delays, supply constraints, reliance on a concentrated shareholder base and key executive retention, and the possibility that it may need additional capital to sustain operations.